Citation Report

List of articles citing

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junctio

DOI: 10.1200/jco.2015.63.5995
Journal of Clinical Oncology, 2016, 34, 1448-54.

Source: https://exaly.com/paper-pdf/65486070/citation-report.pdf
Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
671	New advances in targeted gastric cancer treatment. **2016**, 22, 6776-99		57
670	Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. **2016**, 7, 763-770		1
669	New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. **2016**, 22, 4283-90		26
668	Apatinib for the treatment of gastric cancer. **2016**, 10, 887-92		38
667	Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. **2016**, 14, 1313-1320		16
666	Personalised Treatment in Gastric Cancer: Myth or Reality?. **2016**, 18, 41		11
665	Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. **2016**, 13, 268-70		32
664	Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. *Journal of Clinical Oncology*, **2016**, 34, 3822-3823	2.2	23
663	The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. **2016**, 48, 1283-1289		19
662	Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al. *Journal of Clinical Oncology*, **2016**, 34, 3823-3824	2.2	
661	Is targeted therapy possible for patients with gastric adenocarcinoma?. **2016**, 17, 2371-2374		2
660	Targeting deficient DNA damage repair in gastric cancer. **2016**, 17, 1757-66		10
659	Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. **2016**, 78, 809-14		20
658	Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3821	2.2	18
657	Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?. *Journal of Clinical Oncology*, **2016**, 34, 3823	2.2	11
656	Gastric cancer - clinical and epidemiological aspects. **2016**, 21 Suppl 1, 39-44		62
655	Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. **2016**, 35, 183		12

654	Targeted Treatment of Esophagogastric Cancer. **2016**, 39, 788-794	1
653	Gastric cancer: current and evolving treatment landscape. **2016**, 35, 83	36
652	Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. **2016**, 35, 439-56	32
651	Antiangiogenic therapies in gastric cancer: trusting the pathway. **2016**, 27, 2141-2143	2
650	Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. **2016**, 9, 111	35
649	Apatinib in metastatic gastric cancer: can paclitaxel make the difference?. **2016**, 27, 809	3
648	Austherapiertes Magenkarzinom: Angiogenesehemmer als Alternative?. **2016**, 19, 34-34	
647	Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. **2016**, 95, e4368	22
646	Advanced gastric adenocarcinoma: optimizing therapy options. **2017**, 10, 263-271	16
645	[Novel pharmaceutical treatment approaches for gastric cancer]. **2017**, 38, 87-92	0
644	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. **2017**, 174, 145-172	19
643	Gastric cancer management: Kinases as a target therapy. **2017**, 44, 613-622	21
642	Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. **2017**, 35, 187-194	9
641	Adjuvant therapy for locally advanced gastric cancer. **2017**, 47, 1295-1302	38
640	Novel Targeted Therapies for Esophagogastric Cancer. **2017**, 26, 293-312	10
639	The changing landscape of clinical trial and approval processes in China. **2017**, 14, 577-583	22
638	Advanced gastric cancer: is there an optimal chemotherapy regimen?. **2017**, 2, 123-132	
637	The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. **2017**, 31, 307-318	21

636	A case report of apatinib in treating osteosarcoma with pulmonary metastases. **2017**, 96, e6578		17
635	Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis. **2017**, 96, e6884		23
634	New agents on the horizon in gastric cancer. **2017**, 28, 1767-1775		51
633	Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. **2017**, 5, 549-557		
632	Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis. **2017**, 116, 68-81		26
631	Gastric adenocarcinoma. **2017**, 3, 17036		251
630	Anti-Angiogenics in Gastroesophageal Cancer. **2017**, 1-19		
629	A global burden of gastric cancer: the major impact of China. **2017**, 11, 651-661		58
628	Genetics of Gastric Cancer. **2017**, 97, 345-370		29
627	Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease. **2017**, 13, e528-e530		2
626	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. **2017**, 16, 319-327		7
625	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. **2017**, 13, 2265-2275		8
624	Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. **2017**, 14, 5409-5417		15
623	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. **2017**, 390, 2461-2471		1123
622	Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. **2017**, 7, 13208		28
621	Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. *Cell Death and Disease*, **2017**, 8, e3015	9.8	131
620	Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. **2017**, 84, 184-192		59
619	Coagulation and fibrinolysis in gastric cancer. **2017**, 1404, 27-48		51

618	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?. **2017**, 2, e000206	29
617	Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. **2017**, 43, 1835-1845	3
616	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. **2017**, 22, 1463-1469	17
615	The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis. **2017**, 96, e6301	5
614	Angiogenesis inhibitors in early development for gastric cancer. **2017**, 26, 1007-1017	23
613	High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. **2017**, 96, e5772	14
612	Concurrent apatinib and local radiation therapy for advanced gastric cancer: A case report and review of the literature. **2017**, 96, e6241	6
611	Precision medicine in gastric cancer: where are we now?. **2017**, 2, 193-204	
610	Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC-05 lung cancer cells. **2018**, 17, 911-917	8
609	Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. **2017**, 11, CD004063	39
608	Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review. **2017**, 96, e8507	13
607	Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report. **2017**, 96, e8570	10
606	Apatinib in refractory radiation-induced brain edema: A case report. **2017**, 96, e7358	7
605	Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment. **2017**, 39, 1010428317711033	14
604	101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. **2017**, 93, 243-248	9
603	Milestones in gastric cancer. **2017**, 10, 33-37	0
602	Genomics and epidemiology for gastric adenocarcinomas. **2017**, 37,	6
601	Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. **2017**, 143, 361-368	20

600	Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?. **2017**, 13, 295-298	7
599	Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?. **2017**, 20, 31-42	12
598	Chemotherapy for advanced gastric cancer: future perspective in Japan. **2017**, 20, 102-110	8
597	A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study. **2017**, 96, e9053	29
596	Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. **2017**, 10, 153	53
595	Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report. **2017**, 96, e8725	6
594	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. **2017**, 8, 20510-20515	34
593	Molecular Targeting Therapy for Gastric Cancer: Current Advances and Obstacles. **2017**,	
592	Clinical Implications of Molecular Heterogeneity of Gastric Cancer. **2017**,	
591	Salvage treatment with apatinib for advanced non-small-cell lung cancer. **2017**, 10, 1821-1825	49
590	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. **2017**, 49, 851-868	41
589	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. **2017**, 8, 418-429	18
588	Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. **2017**, 10, 3965-3969	36
587	Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis. **2017**, 10, 1897-1908	6
586	Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. **2017**, 10, 447-452	25
585	Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. **2017**, 10, 4989-4995	15
584	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. **2017**, 12, e0172307	8
583	Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways. **2017**, 15, 253	6

582	New chemotherapies in gastric adenocarcinoma. **2017**, 10, 132-135		
581	Apatinib is effective for treatment of advanced hepatocellular carcinoma. **2017**, 8, 105596-105605		33
580	Anti-VEGF Therapy in Cancer: A Double-Edged Sword. **2017**,		4
579	Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report. **2017**, 10, 5237-5242		5
578	Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. **2017**, 10, 1521-1525		14
577	Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series. **2017**, 10, 837-845		23
576	Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. **2017**, 10, 2289-2295		15
575	Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. **2017**, 8, 42252-42261		36
574	Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. **2017**, 8, 29346-29354		25
573	Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. **2017**, 8, 48253-48262		5
572	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. *Journal of Clinical Oncology*, **2017**, 35, 2279-2287	2.2	74
571	Gastric Cancer in Asia: Unique Features and Management. **2017**, 37, 279-291		18
570	No benefit from ramucirumab in first-line chemotherapy?. **2017**, 2, 30		2
569	Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. **2017**, 2, 11		
568	The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study. **2017**, 2, 29		1
567	The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials. **2018**, 21, 361-371		39
566	Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. **2018**, 97, e9704		28
565	The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: A case report. **2018**, 97, e9598		7

564	Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. **2018**, 1864, 1693-1701	17
563	VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis?. **2018**, 214, 560-564	8
562	Target Therapy for Esophageal Adenocarcinoma. **2018**, 1756, 51-65	2
561	Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. **2018**, 21, 1050-1057	13
560	Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. **2018**, 78, 747-758	92
559	Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. **2018**, 14, 446-452	18
558	Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway. **2018**, 100, 176-183	26
557	Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803. **2018**, 119, 4957-4966	9
556	Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. **2018**, 21, 183-195	11
555	First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy. **2018**, 19, 355-358	
554	Novel targeted therapeutics for MEN2. **2018**, 25, T53-T68	10
553	Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. **2018**, 25, 888-894	4
552	A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. **2018**, 148, 286-290	49
551	Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review. **2018**, 19, 141-144	8
550	Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study. **2018**, 19, 198-204	35
549	Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. **2018**, 14, 204-209	5
548	Apatinib for advanced sarcoma: results from multiple institutionsQoff-label use in China. **2018**, 18, 396	46
547	Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. **2018**, 11, 20	25

546	Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer. **2018**, 78, 28-35	18
545	Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. **2018**, 8, 4602	25
544	A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer. **2018**, 17, e443-e449	25
543	Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. **2018**, 45, 133-150	2
542	Customization of therapy for gastroesophageal adenocarcinoma patients. **2018**, 4, 8-17	1
541	Anti-Angiogenics: Current Situation and Future Perspectives. **2018**, 41, 166-171	99
540	Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. **2018**, 21, 453-463	31
539	Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. **2018**, 154, 437-451	51
538	Medical management of gastric cancer: a 2017 update. **2018**, 7, 123-133	100
537	Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. **2018**, 14, 264-269	26
536	Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study. **2018**, 29, 184-189	7
535	Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review. **2018**, 9, 33734-33738	5
534	The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. **2018**, 97, e11214	9
533	Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials. **2018**, 10, 5505-5514	3
532	Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. **2018**, 9, 377-389	2
531	Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment. **2018**, 97, e13635	9
530	Overexpression of Kin of IRRE-Like Protein 1 (KIRREL) in Gastric Cancer and Its Clinical Prognostic Significance. **2018**, 24, 2711-2719	4
529	Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study. **2018**, 97, e11734	13

528	Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report. **2018**, 97, e11036	1
527	Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report. **2018**, 97, e13105	2
526	The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis. **2018**, 97, e12588	5
525	Thermo/pH dual-responsive core-shell particles for apatinib/doxorubicin controlled release: preparation, characterization and biodistribution. **2018**, 6, 7621-7633	8
524	Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. **2018**, 9, 7175-7181	8
523	Efficacy prediction of targeted therapy for gastric cancer: The current status (Review). **2018**, 18, 1238-1246	3
522	New drug developments in metastatic gastric cancer. **2018**, 11, 1756284818808072	14
521	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. **2018**, 10, 5178-5183	1
520	New therapeutic options opened by the molecular classification of gastric cancer. **2018**, 24, 1942-1961	25
519	The efficacy and safety of apatinib in Ewing@ sarcoma: a retrospective analysis in one institution. **2018**, 10, 6835-6842	6
518	The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials. **2018**, 97, e13259	6
517	Significant Efficacy of Apatinib in a Patient With Hepatocellular Carcinoma Lung Metastases After Liver Transplantation: A Case Report. **2018**, 50, 4042-4045	2
516	Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. **2018**, 11, 6119-6128	27
515	Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer. **2018**, 552, 319-327	7
514	Role of Tyrosine Kinases in Gastrointestinal Malignancies. **2018**,	
513	Emerging Therapies in the Management of Advanced-Stage Gastric Cancer. **2018**, 9, 404	20
512	Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report. **2018**, 11, 5821-5826	7
511	Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients@ decision making?. **2018**, 10, 172-183	

510	Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. *Cell Death and Disease*, **2018**, 9, 1030	9.8	65
509	Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. **2018**, 8, 15837		15
508	Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis. **2018**, 97, e12083		10
507	LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1. **2018**, 10, 4349-4361		8
506	Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials. **2018**, 38, 1109-1123		9
505	The safety of apatinib for the treatment of gastric cancer. **2018**, 17, 1145-1150		30
504	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. **2018**, 19, 1437-1448		210
503	Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends. **2018**, 71, 32-38		6
502	Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report. **2018**, 16, 4614-4620		2
501	Apatinib mesylate tablet in the treatment of advanced malignant melanoma. **2018**, 11, 5333-5338		5
500	Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. **2018**, 54,		32
499	Current therapeutic landscape for advanced gastroesophageal cancers. **2018**, 6, 78		5
498	Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. **2018**, 11, 883-890		4
497	Augmentation of -Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. **2018**, 17, 2353-2364		4
496	Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy. **2018**, 14, 2516-2526		10
495	A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer. **2018**, 19, e831-e842		37
494	Evaluation of the Effects of Apatinib on the Pharmacokinetics of Venlafaxine and O-desmethylvenlafaxine in SD Male Rats by UPLC-MS/MS. **2018**, 123, 721-726		2
493	Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. **2018**, 27, 519-537		19

492	Chemical Therapy. **2018**, 263-281	
491	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. **2018**, 5, 14-20	2
490	Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report. **2018**, 18, 618	8
489	The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. **2018**, 11, 3047-3057	14
488	Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. **2018**, 11, 3407-3413	15
487	Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis. **2018**, 11, 4149-4158	4
486	Traditional Chinese medicine polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis. **2018**, 11, 2685-2698	22
485	Progress in the treatment of solid tumors with apatinib: a systematic review. **2018**, 11, 4137-4147	41
484	Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. **2018**, 12, 2173-2183	18
483	Apatinib-treated advanced medullary thyroid carcinoma: a case report. **2018**, 11, 459-463	5
482	Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. **2018**, 11, 4047-4050	
481	Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. **2018**, 19, 1239-1246	89
480	Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib. **2018**, 11, 2565-2570	12
479	Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. **2017**, 19,	46
478	Novel Systemic Therapies for Advanced Gastric Cancer. **2018**, 18, 1-19	25
477	EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. **2018**, 9, 885-891	8
476	Pilot Dose Comparison of Apatinib in Chinese Patients With Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. **2018**, 103, 3640-3646	11
475	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. **2018**, 95, 344-352	9

474	Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro. **2018**, 11, 4785-4795	17
473	Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. **2018**, 7, 4570-4583	37
472	Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review. **2018**, 19, 1088-1092	10
471	Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. **2018**, 9, 1285-1290	21
470	The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. **2018**, 9, 2773-2777	29
469	Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. **2018**, 297, 1-7	9
468	Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer. **2018**, 38, 3231-3242	13
467	Apatinib inhibits macrophage-mediated epithelial-mesenchymal transition in lung cancer.. **2018**, 8, 21451-21459	9
466	Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. **2018**, 17, 1235-1244	25
465	Gastric Cardiac Cancer. **2018**,	2
464	Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. **2019**, 144, 251-262	1
463	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. **2019**, 9, 618	6
462	Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. **2019**, 98, e15650	14
461	Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. **2019**, 98, e16065	6
460	Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. **2019**, 42, 679-690	23
459	Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. **2019**, 24, e542-e550	53
458	Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. **2019**, 2019, 5692317	5
457	Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. **2020**, 112, 12-29	20

456	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. **2019**, 11, 1758835919848169	
455	Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. **2019**, 9, 470	5
454	Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. **2019** , 11, 1758835919859990	10
453	Realization of ductile regime machining in micro-milling SiCp/Al composites and selection of cutting parameters. **2019**, 233, 4336-4347	10
452	The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). **2019**, 39, 69	12
451	Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. **2019**, 38, 454	15
450	A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients. **2019**, 11, 8869-8876	2
449	Targeted and novel therapy in advanced gastric cancer. **2019**, 8, 25	27
448	Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours. **2019**, 20, 61	5
447	Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis. **2019**, 143, 27-45	6
446	Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. **2019**, 68, 1467-1477	10
445	Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. **2019**, 6, 176	1
444	Gastric cancer: Translating novels concepts into clinical practice. **2019**, 79, 101889	39
443	Influence and mechanism of lung cavitation development on antiangiogenic therapy. **2019**, 8, 500-512	7
442	Late-line treatment in metastatic gastric cancer: today and tomorrow. **2019**, 11, 1758835919867522	21
441	Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. **2019**, 121, 640-646	16
440	Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. **2019**, 7,	15
439	Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance -A Multicenter Randomized Trial. **2019**, 9, 14013	3

438	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. **2019**, 37, 524-530	2
437	Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. **2019**, 215, 816-821	13
436	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. **2019**, 37, 731-737	6
435	Merkel cell carcinoma of the thigh: case report and review of the literature. **2019**, 12, 535-540	1
434	No clear role for angiogenesis inhibitors in first-line therapy for stomach cancer. **2019**, 20, 323-324	2
433	The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution. **2019**, 11, 3583-3591	5
432	Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review. **2019**, 12, 3635-3644	4
431	Surgery for Gastric Cancer. **2019**,	1
430	Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. **2019**, 27, 635-641	9
429	Novel Agents and the Future Perspectives. **2019**, 367-378	
428	Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy. **2019**, 421, 319-359	18
427	Gastric Cancer - From Aetiology to Management: Differences Between the East and the West. **2019**, 31, 570-577	13
426	Anti-angiogenic therapies for gastric cancer. **2019**, 15, 208-217	15
425	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. **2019**, 18, 485-496	6
424	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. **2019**, 121-132	
423	Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. **2019**, 17, 4768-4778	8
422	TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant Association. **2019**, 8,	17
421	Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. **2019**, 19, 117	13

420	Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. **2019**, 12, 2577-2583	13
419	Gastric Cancer In The Precision Medicine Era. **2019**,	
418	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. **2019**, 39, 10	199
417	Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study. **2019**, 12, 1681-1689	4
416	Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models. **2019**, 11, 1349-1362	5
415	Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. **2019**, 51, 1-11	16
414	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. **2019**, 125, 2213-2221	6
413	Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. **2019**, 15, 158-165	1
412	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. **2019**, 12, 27	107
411	Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report. **2019**, 98, e14182	6
410	Optimal management of gastroesophageal junction cancer. **2019**, 125, 1990-2001	17
409	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. **2019**, 19, 1-48	201
408	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. **2019**, 7, 630-643	93
407	Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study. **2019**, 98, e13908	12
406	Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. **2019**, 12, 985-992	17
405	Prognostic value and association of Lauren classification with VEGF and VEGFR-2 expression in gastric cancer. **2019**, 18, 4891-4899	11
404	Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China. **2019**, 9, 1155	7
403	Determination of apatinib and its three active metabolites by UPLC-MS/MS in a Phase IV clinical trial in NSCLC patients. **2019**, 11, 2049-2060	1

402	Apatinib treatment for symptomatic pseudoprogression after standard treatment for glioblastoma multiforme: a case report. **2019**, 8, 752-757	1
401	Antiangiogenic therapy for Wilms tumor in an adult and literature review. **2019**, 30, 640-645	2
400	Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. **2019**, 98, e13924	1
399	Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report. **2019**, 98, e14328	3
398	Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review. **2019**, 98, e14595	3
397	Quantification of the Plasma Concentration of Apatinib by 2-Dimensional Liquid Chromatography. **2019**, 41, 489-496	3
396	Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature. **2019**, 98, e17787	2
395	Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status. **2019**, 98, e17890	2
394	Apatinib as an optional treatment in metastatic colorectal cancer. **2019**, 98, e16919	9
393	Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting. **2019**, 98, e16967	6
392	Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer. **2019**, 12, 9757-9765	5
391	Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study. **2019** , 12, 10579-10585	5
390	Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. **2019**, 12, 9707-9713	6
389	Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review. **2019**, 9, 1180	1
388	Gastric Cancers. **2019**, 245-256	
387	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. **2019**, 30, 19-33	101
386	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. **2019**, 42, 159-179	13
385	Apatinib exerts anti-tumour effects on ovarian cancer cells. **2019**, 153, 165-174	15

384	Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review. **2019**, 124, 319-319	12
383	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. **2019**, 25, 515-523	212
382	The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. **2019**, 20, 321-327	25
381	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. **2019**, 20, 357-366	6
380	Challenges and Opportunities With Oncology Drug Development in China. **2019**, 105, 363-375	7
379	Apatinib-induced hyperammonemic encephalopathy. **2020**, 26, 465-470	4
378	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. **2020**, 38, 478-484	1
377	Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. **2020**, 22, 337-343	5
376	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. **2020**, 23, 133-141	10
375	The synergistic anti-tumor effect of schisandrin B and apatinib. **2020**, 22, 839-849	4
374	S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. **2020**, 99, e18691	1
373	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. **2020**, 23, 510-519	72
372	Molecular pathogenesis and precision medicine in gastric cancer. **2020**, 153-165	1
371	Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. **2020**, 16, 4409-4418	30
370	Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy. **2020**, 84, 743-756	7
369	What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center. **2020**, 16, 23-27	1
368	Cancer of the Esophagus. **2020**, 1174-1196.e6	
367	Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy. **2020**, 12, 1707-1720	8

366	Esophageal Cancer. **2020**,	0
365	Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance. **2020**, 241, 117106	30
364	Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma. **2020**, 31, 966-972	3
363	Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.. **2020**, 9, 4999-5007	
362	Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients. **2020**, 12,	3
361	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. **2020**, 9,	7
360	The Roles of ceRNAs-Mediated Autophagy in Cancer Chemoresistance and Metastasis. **2020**, 12,	10
359	An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. **2020**, 2020, 3852373	7
358	Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. **2020**, 12, 2450-2458	2
357	MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. **2020**, 19, 311-318.e1	1
356	The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution. **2020**, 12, 5255-5264	5
355	Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study. **2020**, 13, 11529-11535	1
354	Pathogenic Analysis of the Bronchoalveolar Lavage Fluid Samples With Pediatric Refractory Pneumonia. **2020**, 10, 553739	3
353	Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma. **2020**, 12, 11523-11526	1
352	Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. **2020**, 11, CD012078	6
351	Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma and. **2020**, 10, 585079	4
350	Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. **2020**, 8, 1233	4
349	Solitary metastasis to the skin and colon from gastric cancer after curative gastrectomy and chemotherapy: A case report. **2020**, 99, e21532	4

348	Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. **2020**, 12, 6977-6985	13
347	Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review. **2020**, 11, 1027	0
346	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. **2020**, 5, 137	33
345	Targeted Therapies in Advanced Gastric Cancer. **2020**, 21, 70	37
344	Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study. **2020**, 12, 5345-5351	2
343	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. **2020**, 15, e0235848	8
342	Circulating Levels of L1-cell Adhesion Molecule as a Serum Biomarker for Early Detection of Gastric Cancer and Esophagogastric Junction Adenocarcinoma. **2020**, 11, 5395-5402	1
341	A Predictive Nomogram for Early Death of Metastatic Gastric Cancer: A Retrospective Study in the SEER Database and China. **2020**, 11, 5527-5535	10
340	Efficacy of Acupuncture and Moxibustion as a Subsequent Treatment after Second-Line Chemotherapy in Advanced Gastric Cancer. **2020**, 2020, 8274021	0
339	Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers. **2020**,	1
338	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). **2020**, 13, 143	61
337	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. **2020**, 12,	1
336	Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. **2020**, 13, 1423-1430	3
335	The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers. **2020**, 11,	0
334	Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report. **2020**, 99, e21600	1
333	Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. **2020**, 15, 205	5
332	Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. **2020**, 21, 1244-1252	24
331	Recent Progress, Challenges, and Prospects in Two-Dimensional Photo-Catalyst Materials and Environmental Remediation. **2020**, 12, 167	35

330	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. **2020**, 12,		7
329	Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. **2020**, 13, 12325-12339		1
328	Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival. **2020**, 12, 10631-10638		1
327	Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report. **2020**, 99, e22925		3
326	Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. **2020**, 8, 1047		12
325	Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. **2020**, 12, 1758835920968472		4
324	Targeted therapies for gastroesophageal cancers. **2020**, 8, 1104		7
323	Recent Developments of Systemic Chemotherapy for Gastric Cancer. **2020**, 12,		21
322	Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres. **2020**, 11, 366-375		7
321	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. **2020**, 20, 133		1
320	Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis. **2020**, 10, 513		2
319	TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. **2020**, 152, 102987		3
318	Mining the role of angiopoietin-like protein family in gastric cancer and seeking potential therapeutic targets by integrative bioinformatics analysis. **2020**, 9, 4850-4863		5
317	Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study. **2020**, 13, 4457-4464		3
316	A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients. **2020**, 16, 253-259		
315	Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7. *Cell Death and Disease*, **2020**, 11, 169	9.8	28
314	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. **2020**, 28, 127-133		4
313	Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review. **2020**, 21, 583-589		4

312	Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. **2020**, 130, 12-19	15
311	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. **2020**, 23, 689-698	9
310	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. **2020**, 3, e200363	15
309	Recent researches for dual Aurora target inhibitors in antitumor field. **2020**, 203, 112498	0
308	Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab. **2020**, 24, 100189	1
307	Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. **2020**, 9, 5899-5907	7
306	Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the Gene Polymorphism. **2020**, 13, 603-613	12
305	Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway. **2020**, 69, 153184	17
304	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. **2020**, 14, 275-284	5
303	A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. **2020**, 247, 117402	15
302	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. **2020**, 25, e68-e74	5
301	Apatinib-induced Grade 3 hand-foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report. **2020**, 33, e13241	1
300	The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-B (NF-B) and mitogen-activated protein kinase (MAPK) signaling pathways. **2020**, 27, 613-620	25
299	Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. **2020**, 25, e1464-e1472	10
298	Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. **2020**, 25, 1223-1232	12
297	Next generation sequencing in gastric or gastroesophageal adenocarcinoma. **2020**, 5, 56	2
296	Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. **2020**, 10, 517	4
295	The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. **2020**, 25, 1195-1205	10

294	Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. **2020**, 10, 6058	15
293	Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review. **2020**, 21, 590-596	3
292	An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202). **2020**, 12, 1758835920905424	6
291	Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway. **2020**, 10, 217	20
290	Restrains Apatinib Resistance in Human Gastric Cancer Cells Via Downregulating. **2021**, 36, 95-105	3
289	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. **2021**, 16, 299-309	25
288	Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial. **2021**, 26, e374-e381	5
287	Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial. **2021**, 22, e211-e214	3
286	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. **2021**, 27, 1296-1304	32
285	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. **2021**, 144, 49-60	7
284	Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. **2021**, 113, 665-679	1
283	Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. **2021**, 24, 327-340	4
282	Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC. **2021**, 20, 15330338211011968	1
281	Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. **2021**, 13, 17588359211039047	0
280	Gastric Cancer Harboring an Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study. **2021**, 14, 545-550	2
279	Progress of Gastric Cancer Surgery in the era of Precision Medicine. **2021**, 17, 1041-1049	5
278	Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. **2021**, 10, 1971418	7
277	Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. **2021**, 13, 17588359211013626	4

276	Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. **2021**, 12, 2035-2044	
275	Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract. **2021**, 21, 511-522	2
274	Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study. **2021**, 26, 670-683	2
273	Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma. **2020**, 10, 601175	1
272	Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. **2021**, 14, 101004	1
271	Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report. **2021**, 100, e24390	
270	Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. **2021**, 21, 315	3
269	Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report. **2021**, 32, 469-473	1
268	Human plasminogen-derived N-acetyl-Arg-Leu-Tyr-Glu antagonizes VEGFR-2 to prevent blood-retinal barrier breakdown in diabetic mice. **2021**, 134, 111110	2
267	Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients.. **2021**, 10, 627-636	
266	The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study. **2021**, 21, 189	2
265	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. **2021**, 10,	6
264	An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer. **2021**, 21, 267	
263	Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. **2021**, 9, 612451	3
262	Molecular targeted treatment and drug delivery system for gastric cancer. **2021**, 147, 973-986	8
261	Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. **2021**, 24, 642-654	12
260	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. **2021**, 18, 473-487	32
259	Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. **2021**, 27, 3069-3078	13

258	Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. **2021**, 14, 1041-1055	5
257	The impact of recent next generation sequencing and the need for a new classification in gastric cancer. **2021**, 50-51, 101730	6
256	Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2. **2021**, 11, 6993	3
255	Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. **2021**, 13, 8408-8420	2
254	Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial. **2021**, 12, 642511	4
253	Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report. **2021**, 14, 1989-1995	1
252	Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity. **2021**, 10,	3
251	Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report. **2021**, 11, 668992	2
250	Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways. **2021**, 23,	6
249	Maintenance in gastric cancer: New life for an old issue?. **2021**, 160, 103307	1
248	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. **2021**, 115, 105222	2
247	Apatinib combined with S-1 as second-line therapy in advanced gastric cancer. **2021**, 100, e25630	1
246	Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study. **2021**, 11, 659217	1
245	Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report. **2021**, 49, 3000605211016146	1
244	Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report. **2021**, 21, 218	2
243	Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor. **2021**, 41,	
242	Association Between Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study. **2021**, 14, 2703-2714	2
241	Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation. **2021**, 11, 676092	0

240	Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer. **2021**, 21, 702	2
239	Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review. **2021**, 13, 4447-4454	1
238	Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report. **2021**, 14, 3983-3989	0
237	Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway. **2021**, 9, 679806	5
236	Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. **2021**, 4, e2116240	4
235	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. **2021**, 41, 747-795	36
234	Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?. **2021**, 12, 557-564	2
233	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. **2021**, 6, 559-568	20
232	Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression. **2021**, 14, 91	1
231	Molecularly Targeted Therapies for Gastric Cancer. State of the Art. **2021**, 13,	3
230	Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study. **2021**, 9, 714127	3
229	Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study. **2021**, 14, 4499-4508	0
228	Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study. **2021**, 12, 1416-1427	1
227	Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer. **2021**, 96-107	
226	Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway. **2021**, 13, 20738-20747	1
225	Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC. **2021**, 16, 1426-1428	
224	The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. **2021**, 13, 6989-6998	2
223	Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. **2021**, 11, 728854	3

222	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. **2021**, 26, e1704-e1729	4
221	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. **2021**, 13,	3
220	Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. **2021**, 14, 4859-4865	0
219	PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer. **2021**, 99, 107929	2
218	PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway. **2021**, 53, 1602-1613	3
217	Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. **2021**, 18, 2276-2284	4
216	An unresectable gastric cancer with bulky lymph node metastases treated with SOX chemotherapy plus apatinib followed by D3 radical gastrectomy: a case report.. **2021**, 10, 537-545	
215	Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. **2021**, 12, 1555-1562	4
214	Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. **2020**, 9, 5008-5014	9
213	A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11). **2021**, 26, e925-e935	7
212	Progress and challenges in gastroesophageal cancer. **2020**, 44, 100590	4
211	Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. **2020**, 200, 112482	6
210	Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. **2021**, 78, 148-161	7
209	The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma. **2020**, 26, e927221	3
208	Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway. **2017**, 12, e0177335	13
207	Apatinib inhibits tumor growth and angiogenesis in PNET models. **2019**, 8, 8-19	3
206	Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. **2016**, 7, 59236-59244	40
205	Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. **2017**, 8, 64471-64480	47

204	Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis. **2017**, 8, 97565-97570	2
203	Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. **2017**, 8, 66248-66253	18
202	Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. **2017**, 8, 110774-110784	6
201	Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. **2018**, 9, 8120-8132	2
200	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. **2018**, 9, 16213-16219	6
199	Treatment-related toxicities of apatinib in solid tumors: a meta-analysis. **2018**, 9, 32262-32270	3
198	Apatinib as targeted therapy for sarcoma. **2018**, 9, 24548-24560	12
197	Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. **2020**, 11, 535-549	15
196	Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. **2020**, 17, 501-512	6
195	Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma. **2020**, 8, 1677	8
194	Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report. **2019**, 7, 149	2
193	First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report. **2019**, 7, 181	7
192	PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.. **2020**, 9, 5315-5322	2
191	Clinical significance of gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy. **2019**, 31, 620-631	1
190	Current Molecular Targeted Agents for Advanced Gastric Cancer. **2020**, 13, 4075-4088	11
189	Concordance Between Watson for Oncology and a Multidisciplinary Clinical Decision-Making Team for Gastric Cancer and the Prognostic Implications: Retrospective Study. **2020**, 22, e14122	10
188	Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. **2020**, 27, S173-S180	3
187	Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. **2016**, 22, 5896-908	7

186	Progress in systemic therapy of advanced hepatocellular carcinoma. **2016**, 22, 6582-94	39
185	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. **2017**, 23, 7478-7488	19
184	Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. **2019**, 25, 5773-5788	45
183	[Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment]. **2017**, 20, 761-768	5
182	[A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib]. **2018**, 21, 880-884	2
181	Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study. **2020**, 31, e2	10
180	Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the polymorphism. **2020**, 20, 3035-3045	4
179	Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma. **2020**, 20, 52	6
178	Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung. **2017**, 54, 547-549	2
177	Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer. **2020**, 57, 13-17	1
176	Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer. **2020**, 52, 406-418	3
175	Precision medicine in gastric cancer. **2019**, 11, 804-829	40
174	Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. **2019**, 11, 518-526	8
173	Tumor progression-dependent angiogenesis in gastric cancer and its potential application. **2019**, 11, 686-704	21
172	Molecular classifications of gastric cancers: Novel insights and possible future applications. **2017**, 9, 194-208	38
171	Target Therapy and Immunotherapy in Gastric Cancer. **2021**, 225-233	
170	Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. **2021**, 11, 749083	2
169	Ramucirumab plus paclitaxel for gastric cancer in China. **2021**, 6, 975-976	

168	Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. **2021**, 6, 1015-1024	4
167	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. **2021**, 13,	2
166	A Bayesian network meta-analysis on systemic therapy for previously treated gastric cancer. **2021**, 167, 103505	1
165	Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. **2021**, 11, 734323	1
164	Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. **2021**, 41, 1173-1182	11
163	Radiotherapy in Gastric Cancer with Peritoneal Carcinomatosis. **2017**, 87-101	1
162	Targeted Therapy in Advanced Gastric Cancer. **2017**, 61-76	
161	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. **2018**, 191-224	
160	Esophageal and Gastroesophageal Junction Tumors. **2019**, 55-71	
159	Anti-angiogenics in Gastroesophageal Cancer. **2019**, 395-414	
158	BIOMARKERS, NEOANGIOGENESIS AND GROWTH FACTORS IN PANCREATIC CANCER. **2019**, 6, 51-64	1
157	Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report. **2019**, 7, 3881-3886	2
156	Systemic Treatment for Metastatic or Recurrent Disease. **2020**, 275-287	
155	Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies. **2020**, 20, 1961-1966	0
154	Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma. **2021**, 11, 728253	1
153	Apatinib-Induced Multiple Organ Hemorrhage: A Case Report. **2020**, Publish Ahead of Print,	0
152	Individualized treatment for gastric cancer with rib metastasis: A case report. **2020**, 12, 555-563	
151	Emerging Roles of Phytochemicals in the Pathobiology and Management of Esophageal Cancer. **2020**, 169-187	

150	Gene Network Cancer Prediction Method Based on Multi-group Algorithm. **2020**, 345-350	
149	Monoclonal Antibody Therapy Against Gastrointestinal Tract Cancers. **2020**, 97-111	
148	A Clinical Study on the Expression of miR-195 in Cardiac Carcinoma. **2020**, 22,	
147	Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports. **2020**, 8, 1326-1336	
146	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. **2021**, 15, 451-462	0
145	[Mechanism and Prospect of Radiotherapy Combined with Apotatinib?in the Treatment of Non-small Cell Lung Cancer]. **2017**, 20, 847-851	
144	OnclncRNA-626 promotes malignancy of gastric cancer via inactivated the p53 pathway through interacting with SRSF1. **2019**, 9, 2249-2263	9
143	Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors. **2020**, 10, 249-262	7
142	Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202). **2020**, 10, 987-996	2
141	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. **2021**, 21, 62	
140	G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer. **2021**, 11, 3070-3084	2
139	Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial. **2021**, 13, 9015-9023	
138	Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. **2021**, 1-16	0
137	Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. **2021**,	0
136	The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. **2021**, 2021, 8169012	
135	Comparing the Effectiveness and Safety of Sorafenib Plus TACE with Apatinib Plus Tace for Treating Patients with Unresectable Hepatocellular Carcinoma: A Multicentre Propensity Score Matching Study.	
134	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.. **2022**,	0
133	Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.. **2020**, 9, 6392-6401	

132	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. **2020**, 21, 62	
131	Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study.. **2022**, 10, 100	1
130	A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.. **2022**, 10, 101	
129	The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib.. **2022**, 13, 15-20	
128	Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study.. **2021**, 11, 791912	1
127	Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.. **2022**,	1
126	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.. **2022**, 89, 255	1
125	Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. **2022**, 29-66	0
124	Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.. **2021**, 12, 784861	0
123	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.. **2022**, 10, 441	0
122	Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. **2022**, 5, 29	
121	Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study.. **2022**, 14, 455-463	1
120	CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy.. **2022**, 12, 758863	2
119	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.. **2022**, 10,	1
118	Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.. **2022**, 13, 768028	0
117	Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.. **2022**, 10, 205	0
116	Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.. **2022**, 2022, 4233782	
115	Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.. **2022**, 15, 267-275	0

114	Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.. **2022**, 14,	0
113	Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review.. **2022**, 10, 377	0
112	The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.. **2022**,	4
111	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial.. **2022**, 3, 100312	0
110	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report.. **2022**, 10, 3593-3600	0
109	Efficacy and safety of apatinib in radiation-induced brain injury among head and neck cancer: an open-label, single-arm, phase 2 study.. **2022**,	0
108	Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.. **2022**, 20, 107	1
107	Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.. **2022**, 120439	1
106	Molecular Pathogenesis, Targeted Therapies, and Future Perspectives for Gastric Cancer.. **2021**,	4
105	Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.. **2021**, 27, 1610008	1
104	Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension. **2021**, 40,	1
103	Patients with brain metastases from gastric cancer.. **2022**, 3008916221084361	
102	Image_1.tif. **2020**,	
101	Image_2.TIF. **2020**,	
100	Image_3.tif. **2020**,	
99	Image_4.tif. **2020**,	
98	Table_1.DOCX. **2020**,	
97	Table_1.DOC. **2019**,	

96	Table_1.DOCX. **2020**,	
95	Licoflavone A Suppresses Gastric Cancer Growth and Metastasis by Blocking the VEGFR-2 Signaling Pathway.. **2022**, 2022, 5497991	
94	Screening Protein Prognostic Biomarkers for Stomach Adenocarcinoma Based on The Cancer Proteome Atlas.. **2022**, 12, 901182	1
93	Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.. **2022**, 2022, 4322404	0
92	Progress and remaining challenges in comprehensive gastric cancer treatment. **2022**, 1,	0
91	Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study.. **2022**, 13, 722-731	0
90	Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.. **2022**, 20, 154	0
89	Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.. **2022**, 54, 1357-1371	1
88	Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma. **2022**,	0
87	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.. **2022**,	16
86	Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein-Barr Virus DNA after Radiotherapy.. **2022**,	0
85	Molecular pathogenesis and emerging targets of gastric adenocarcinoma.. **2022**, 125, 1079-1095	1
84	Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients. **2022**, 101962	1
83	Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. **2022**, 14, 2758	0
82	The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. 12,	0
81	Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer. 9,	0
80	Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. 13,	1
79	Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer.	5

78	Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.		0
77	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.		0
76	Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study. 12,		0
75	Association of Apatinib and Breast Cancer: A systematic review and meta-analysis. **2022**, 101818		
74	PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. 13,		0
73	A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer. 12,		0
72	Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer. *Cell Death and Disease*, **2022**, 13,	9.8	0
71	Gastric Cancer Secreted miR-214-3p Inhibits the Anti-Angiogenesis Effect of Apatinib by Suppressing Ferroptosis in Vascular Endothelial Cells..		
70	Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. **2022**, 188775		1
69	Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer. 13,		0
68	Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis. 12,		
67	A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. **2022**, 14, 4084		
66	Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. 13,		1
65	Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option. 13,		0
64	Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S-1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma. **2022**, 24,		
63	Anti-proliferation effects of Apatinib in combination with Curcumin in breast cancer cells. **2022**,		0
62	Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats. 13,		0
61	Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer. **2022**, 97-134		0

60	Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. **2022**, 14, 175883592211180	1
59	European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. **2022**, 14, 175883592211188	0
58	Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). **2022**, 20,	0
57	Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry. 1-13	0
56	Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done. **2022**, 29, 6433-6444	1
55	WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3/PKM2 axis. 13,	0
54	Apatinib enhances chemosensitivity of ABT -199 in diffuse large B-cell lymphoma.	0
53	Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. **2022**, 8,	0
52	Apatinib and temozolomide in children with recurrent ependymoma: A case report. **2022**, 101, e30529	0
51	Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report. **2022**, 20,	1
50	Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer. **2022**, 2022, 1-9	0
49	A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer.	0
48	Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. 12,	1
47	Esophageal cancer in China: Practice and research in the new era.	1
46	Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. **2022**, 33,	1
45	Molecular Pathology of Gastric Cancer. **2022**, 22, 264	0
44	Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study. **2022**, 22, 408	0
43	Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.	0

42	Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer.	0
41	Signaling pathways and therapeutic interventions in gastric cancer. **2022**, 7,	0
40	Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer. **2022**, 14, 4888	1
39	Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single- Arm, Phase II Trial.	0
38	Small molecule inhibitors targeting the cancers. **2022**, 3,	0
37	Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12,	0
36	Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma. **2022**, 11, 6380	0
35	Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer. 12,	0
34	Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma. 12,	0
33	Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. 13,	0
32	Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor. 12,	0
31	Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer. **2022**, 14, 5615	0
30	Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study. 13,	0
29	Current developments in gastric cancer: from molecular profiling to treatment strategy.	2
28	State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers. 38-46	0
27	The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. 12,	0
26	TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.	0
25	Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE).	0

24	Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report. **2022**, 25,	0
23	Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review. 13,	0
22	Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. **2023**, 14,	2
21	High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study. **2023**, 22, 153303382211505	0
20	Apatinib in recurrent or metastatic head and neck cancer patients.	0
19	LDP alleviates TKI-induced proteinuria through reversing the expression of RelA in renal tissues. 10,	0
18	Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. 23,	0
17	PDT for Gastric Cancer the view from China. **2023**, 42, 103366	0
16	Apatinib with first-generation EGFR-TKIs as second-line treatment for patients with advanced non-small cell lung cancer with acquired resistance: a retrospective case series analysis.	0
15	Identifying predictive biomarkers of apatinib in third-line treatment of advanced colorectal cancer through comprehensive genomic profiling. **2023**, 34, 431-438	0
14	In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation. **2023**, 23,	0
13	Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric cancer. **2023**, 189, 106696	0
12	Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer. **2023**, 16,	0
11	Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis. 13,	0
10	Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. **2023**,	0
9	Sintilimab Plus Apatinib and Chemotherapy as Second-/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. **2023**, 23,	0
8	Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. **2023**, 21, 2172-2187	0
7	The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial. **2023**, 21,	0

6	Targeting angiogenesis in oncology, ophthalmology and beyond.	0
5	Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study. **2023**, 21,	0
4	Treatment Status and Progress of Advanced Gastric Cancer. **2023**, 13, 5419-5426	0
3	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.	0
2	The Efficacy and Safety of the Shouzu Ning Decoction Treatment Versus Halometasone Plus Celecoxib Treatment in Patients With Grade 2 HFSR: A Randomized Clinical Trial. **2023**, 22, 153473542311687	0
1	Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor. **2023**, 91, 491-499	0